Patents Issued in January 19, 2017
-
Publication number: 20170014418Abstract: The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.Type: ApplicationFiled: June 20, 2016Publication date: January 19, 2017Inventors: Eddy W. Yue, Andrew P. Combs, Brent Douty
-
Publication number: 20170014419Abstract: Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.Type: ApplicationFiled: April 3, 2015Publication date: January 19, 2017Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kenji KANGAWA, Hiroshi HOSODA, Takashi NOJIRI
-
Publication number: 20170014420Abstract: The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.Type: ApplicationFiled: September 28, 2016Publication date: January 19, 2017Applicant: THE GEORGE WASHINGTON UNIVERSITYInventors: William B. WEGLICKI, Iu Tong MAK
-
Publication number: 20170014421Abstract: The present invention relates to piperazine phenothiazine derivatives useful as therapeutic agents for treating spasticity, particularly following an ischemia or traumatic injury, or compression syndrome. The invention further relates to a pharmaceutical composition comprising a compound of the invention for treating spasticity.Type: ApplicationFiled: March 10, 2015Publication date: January 19, 2017Inventors: Pascale BOULENGUEZ, Sylvie LIABEUF, Laëtitia GOURMAND, Annelise VIALLAT-LIEUTAUD, Laurent VINAY
-
Publication number: 20170014422Abstract: The present invention relates to stable pharmaceutical compositions comprising ivabradine hydrochloride polymorph IV, characterized in that the composition is stabilized by a moisture barrier with a WVTR of less than 0.35 g/m2/day at 38° C./90% RH. The invention further relates to the use of said composition as a medicament, particularly in the treatment of stable angina pectoris and chronic heart failure.Type: ApplicationFiled: July 22, 2014Publication date: January 19, 2017Applicant: SYNTHON B.V.Inventors: LISA BAKKER-HOLMDAHL, DEEPAK MURPANI
-
Publication number: 20170014423Abstract: This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.Type: ApplicationFiled: September 28, 2016Publication date: January 19, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
-
Publication number: 20170014424Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
-
Publication number: 20170014425Abstract: The present invention is related to a pharmaceutical composition and health food for preventing or treating hearing loss, wherein the pharmaceutical composition and health food contain carbenoxolone or its pharmaceutically acceptable salts as an effective component. More particularly, a composition including carbenoxolone or its pharmaceutically acceptable salts as an effective component is provided as a pharmaceutical composition for preventing or treating ototoxic hearing loss due to the carbenoxolone or its pharmaceutically acceptable salts prevent damages on auditory cells from ototoxic drugs such as cisplatin anticancer drugs, and the composition may be used as a drug for treating noise-induced hearing loss and age-related hearing loss, as well as ototoxic hearing loss.Type: ApplicationFiled: July 13, 2016Publication date: January 19, 2017Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Yun-Hoon CHOUNG, Yeon Ju KIM
-
Publication number: 20170014426Abstract: The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.Type: ApplicationFiled: July 29, 2016Publication date: January 19, 2017Inventors: Michele RESCHE-RIGON, Delphine LEVY, Erin GAINER, Anne GOMPEL, Patricia FORGEZ, Laudine DESREUMAUX-COMMUNAL
-
Publication number: 20170014427Abstract: The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The methods of curing a patient of migraines having trigeminal or occipital neuralgia involves administering, by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves.Type: ApplicationFiled: September 27, 2016Publication date: January 19, 2017Inventor: Faro Owiesy
-
Publication number: 20170014428Abstract: Injectable pharmaceutical compositions, methods of use and formulation are disclosed. The compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Inventors: Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
-
Publication number: 20170014429Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).Type: ApplicationFiled: December 23, 2014Publication date: January 19, 2017Inventors: Shunlin REN, Felix THEEUWES, James E. BROWN, WeiQi LIN
-
Publication number: 20170014430Abstract: Provided is a cycloartenol-containing composition which can be used as a material for food and beverage, cosmetics, or the like, and has high biological activities. The cycloartenol-containing composition has a cycloartenol content of more than 37% by mass, a 24-methylenecycloartanol content of more than 5% by mass, and a sum content of cycloartenol and 24-methylenecycloartanol of more than 76% by mass, relative to the total mass of sterols.Type: ApplicationFiled: March 6, 2015Publication date: January 19, 2017Applicant: KAO CORPORATIONInventors: Kohjiro HASHIZUME, Fumiaki OKAHARA
-
Publication number: 20170014431Abstract: A rocuronium bromide injection solution-prefilled syringe of the present invention includes a syringe comprising an outer cylinder made of synthetic resin, a gasket which is accommodated inside the outer cylinder and liquid-tightly slidable inside the outer cylinder, and a seal member for sealing a distal end opening of the outer cylinder; and a rocuronium bromide injection solution filled inside the syringe. The gasket is formed by vulcanized chlorinated butyl rubber added calcined clay, and said calcined clay is only added as an inorganic filler classified as an inorganic reinforcing agent and an inorganic filling agent.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Applicant: Terumo Kabushiki KaishaInventors: Akira Yoshida, Yuki Watanabe, Aiko Horiuchi, Hiroki Yoshikawa
-
Publication number: 20170014432Abstract: The invention relates to compositions and methods for reducing chronic low-level inflammation associated with chronic conditions. Specifically, the invention relates to compositions of hydrophobic derivatives of aspirin and/or hydrophobic derivatives of sesamol in combination with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and their methods for reducing chronic low-level inflammation associated with chronic conditions including obesity, metabolic syndrome, diabetes, cardiovascular disease, cancer, auto-immune disorders, ocular and neurological disorders in a mammal.Type: ApplicationFiled: March 6, 2015Publication date: January 19, 2017Inventor: Barry D. SEARS
-
Publication number: 20170014433Abstract: The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.Type: ApplicationFiled: September 27, 2016Publication date: January 19, 2017Inventors: Howard FEIN, Mindy B. Berlin
-
Publication number: 20170014434Abstract: In an effort to discover therapies for treating HSP70 related diseases, a previously unidentified hydrophobic pocket was found in the C-terminal domain of DnaK and of human HSP70. A novel chemical scaffold was also discovered for identifying compounds that treat diseases related to this hydrophobic pocket. The compounds have the structure of the formula (I), wherein L, M, and R1-R5 are defined herein and are, therefore, in these therapies, optionally with other pharmaceutical agents such as genotoxic agents. Accordingly these compounds are useful in inhibiting HSP70 or DnaK, reducing HSP70 in mitochondria of a cancer cell, treating malignant neoplastic disease, or inhibiting or reducing bacterial growth. These compounds also resulted in novel methods of screening for a HSP70 inhibitor or DnaK inhibitor by using the three-dimensional structure of the hydrophobic pocket in DnaK or HSP70.Type: ApplicationFiled: February 26, 2015Publication date: January 19, 2017Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: Donna L. George, Maureen E. Murphy, Julia I-Ju Leu
-
Publication number: 20170014435Abstract: There is disclosed is a method of treating cancer using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.Type: ApplicationFiled: September 28, 2016Publication date: January 19, 2017Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
-
Publication number: 20170014436Abstract: The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome.Type: ApplicationFiled: May 10, 2016Publication date: January 19, 2017Inventors: Joseph M. Fayad, Jerome Schentag
-
Publication number: 20170014437Abstract: Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.Type: ApplicationFiled: April 3, 2015Publication date: January 19, 2017Applicants: Syracuse University, The Research Foundation for the State University o f New YorkInventors: Yan-Yeung Luk, Guirong Wang
-
Publication number: 20170014438Abstract: The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.Type: ApplicationFiled: June 23, 2016Publication date: January 19, 2017Applicants: Changshu HKBU Technology Company LimitedInventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Jinjin Wang, Zhijun Yang, Aiping Lu, Albert Sun Chi Chan
-
Publication number: 20170014439Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 levels, treating inflammation, and treating symptoms of metabolic syndrome.Type: ApplicationFiled: March 31, 2015Publication date: January 19, 2017Inventors: Robert M. Brewster, John A. Manthey
-
Publication number: 20170014440Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.Type: ApplicationFiled: February 16, 2016Publication date: January 19, 2017Inventors: Joseph Desimone, Yogen Saunthararajah
-
Publication number: 20170014441Abstract: Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0/G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium/iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes.Type: ApplicationFiled: January 21, 2016Publication date: January 19, 2017Inventor: Michael Mingzhao Xing
-
Publication number: 20170014442Abstract: A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprises administering to a patient in need thereof an effective exposure of an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO.2), wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is not administered with corticosteroids or glucocorticosteroids.Type: ApplicationFiled: September 14, 2016Publication date: January 19, 2017Inventors: Charlotte ADMYRE, Arezou ZARGARI, Oliver VON STEIN, Petra VON STEIN
-
Publication number: 20170014443Abstract: Compositions containing hemicelluloses, citric acid and glucose syrup, fructose or sucrose in combination with polyphenols and prebiotics, methods of preparing the compositions, and methods of treating humans or animals with the composition are provided. Also provided is a method for increasing growth rate, improving feed efficiency and decreasing scour after weaning in an animal by administering an effective amount of the composition to the animal. The prebiotics preferably are not consumed by human alimentary enzymes or harmful bacteria, such as putrefactive or pathogenic bacteria, and are consumed by beneficial bacteria, such as bifidobacteria, in the gastrointestinal tract. The polyphenols preferably decrease the amount of harmful bacteria in the gastrointestinal tract. The compositions can optionally contain a carrier or be used as a feed addition and are administered to humans or other animals in an amount sufficient to treat the gastrointestinal disorder.Type: ApplicationFiled: July 19, 2016Publication date: January 19, 2017Inventor: Manuel Serrano
-
Publication number: 20170014444Abstract: An object of the present invention is to provide an agent for sedating the response of skin to external stimulation. The aforementioned object was achieved by finding a component that promotes CD39 gene expression in Langerhans cells. More specifically, the present invention is based on the finding that the combination of carboxymethyl-beta glucan or a salt thereof polyoxyethylene (POE)/polyoxypropylene (POP) random copolymer dimethyl ether and rosewater promotes CD39 gene expression.Type: ApplicationFiled: March 12, 2014Publication date: January 19, 2017Applicant: SHISEIDO COMPANY, LTDInventors: Junichi HOSOI, Kaori INOUE, Shoko YAMADA, Minako SATO
-
Publication number: 20170014445Abstract: This invention provides (a) nanoparticle made of: sugar-beet pectin; and a bioactive compound (such as a nutraceutical or a drug) bound to sugar-beet pectin. The invention further provides foods, beverages, including clear ones, or pharmaceutical preparations, which are supplemented with the nanoparticles made of: sugar-beet pectin; and a hydrophobic bioactive compound bound to sugar-beet pectin. The process of making the nanoparticles of the invention, and methods for supplementing foods or beverages or pharmaceutical preparations with bioactive compounds via the nanoparticles of the invention are also provided.Type: ApplicationFiled: December 11, 2014Publication date: January 19, 2017Inventor: Yoav LIVNEY
-
Publication number: 20170014446Abstract: The invention provides methods for the treatment of diseases and conditions relating to galectin 3 using a galectin-3 inhibitor, such as a modified pectin (e.g., GCS-100). Also described are methods for conjoint therapy, and methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy.Type: ApplicationFiled: March 10, 2015Publication date: January 19, 2017Applicant: LA JOLLA PHARMACEUTICAL COMPANYInventors: James Rolke, George Tidmarsh
-
Publication number: 20170014447Abstract: The present invention provides the use of an alginate Io inhibit pancreatic lipase. The use may be directed to the control of weight in animals including human beings. Preferably the fraction of guluronate dimers in the alginate is at least 0.5.Type: ApplicationFiled: July 27, 2016Publication date: January 19, 2017Inventors: Johnathan Craig Richardson, Peter William Dettmar, Matthew David Wilcox, Iain Andrew Brownlee, Jeffrey Peter Pearson
-
Publication number: 20170014448Abstract: The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.Type: ApplicationFiled: July 14, 2016Publication date: January 19, 2017Inventors: Hongzhe Sun, Chi-Fung Godfrey Chan, Shing Chan, Runming Wang
-
Publication number: 20170014449Abstract: Disclosed herein include various embodiments related to site-specific epigenetic editing of biological cells. Various embodiments relate to fusion protein constructs and methods of using the same for site-specific epigenetic editing of biological cells. Various embodiments relate to fusion protein constructs that utilize endogenous epigenetic editing effector agents for site-specific editing of biological cells.Type: ApplicationFiled: July 13, 2015Publication date: January 19, 2017Inventors: Mahalaxmi Gita Bangera, Michael H. Baym, Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight, Elizabeth A. Sweeney
-
Publication number: 20170014450Abstract: Disclosed are methods, compositions, devices, and kits for the isolation of brain-specific exosomes. Specifically, methods, compositions, devices, and Unbound kits comprising an isolated brain-specific extracellular vesicle or exosome joined to a first binding agent that is specific for tau, ?-amyloid, SlOO ?, neuron-specific enolase, glycoprotein A2B5, CD133, NQ01, synaptophysin, neuronal nuclei, MAB 1569, polysialic acid-neural cell adhesion molecule (PSA-NCAM), or neurogenic differentiation 1 (NeuroD or Beta2), or glycosylated or phosphorylated forms of these molecules, are provided.Type: ApplicationFiled: February 26, 2015Publication date: January 19, 2017Applicant: EXOSOME SCIENCES, INC.Inventors: James Joyce, Douglas Taylor, Cicek Taylor
-
Publication number: 20170014451Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.Type: ApplicationFiled: March 22, 2016Publication date: January 19, 2017Inventors: M. Edward Medof, Feng Lin
-
Publication number: 20170014452Abstract: The present disclosure provides compositions and methods for treating a peritoneal cancer in a subject. The methods include administering a T cell which is genetically modified to express a chimeric T cell receptor protein. The chimeric T cell receptor protein may include a T cell receptor signaling domain fused to the tumor associated antigen-binding fragment of an antibody or a T cell receptor signaling domain fused to a naturally occurring ligand which specifically binds to a tumor cell surface protein. The compositions and methods disclosed herein are therapeutically effective to reduce, for example, tumor burden, abdominal ascites, peritoneal mucin, or serum tumor marker levels.Type: ApplicationFiled: July 14, 2016Publication date: January 19, 2017Inventors: Steven C. Katz, Richard Junghans
-
Publication number: 20170014453Abstract: Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8+ T cells as DLI following allogeneic HCT, where the cells are administered at a suitable time following transplantation. The methods provide for a more complete donor chimerism, and have the further benefit of killing tumor cells without GVHD. The memory CD8+ T cells may include one or both of central and effector memory T cells, usually both.Type: ApplicationFiled: July 22, 2016Publication date: January 19, 2017Inventors: Samuel Strober, Suparna Dutt, Robert Lowsky
-
Publication number: 20170014454Abstract: A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Erik John Woods, Shelly J. Zacharias, Sreedhar Thirumala
-
Publication number: 20170014455Abstract: Methods and compositions are described herein for generating brown adipose cells and tissues that involve contacting one or more starting cells with bexarotene, ciclopirox, IOX2, or combinations thereof. When administered in vivo, subjects receiving bexarotene, ciclopirox, IOX2, or combinations thereof have reduced white adipose tissue mass (with enhanced beige features) as well as enlarged brown fat tissue compared to a control mammal that did not receive the bexarotene, ciclopirox, IOX2, or combinations thereof. The subjects also have increased energy expenditure, generate more heat, and/or consume more oxygen, than a control mammal that did not receive the bexarotene, ciclopirox, IOX2, or combinations thereof.Type: ApplicationFiled: March 12, 2015Publication date: January 19, 2017Inventors: Baoming Nie, Sheng Ding
-
Publication number: 20170014456Abstract: Methods of treating endometrial dysfunction are described including retrieval of endometrial cells including endometrial stem cells from a fertile donor and transplantation of endometrial cells or tissue into a host suffering from endometrial dysfunction. In certain embodiments, methods include genetic modification, tissue culturing, or cryopreservation of the endometrial cells prior to transplantation. In various aspects, endometrial cells are retrieved from an individual during peak fertility and banked for autologous transplantation at a later time.Type: ApplicationFiled: July 13, 2016Publication date: January 19, 2017Inventor: Piraye Yurttas Beim
-
Publication number: 20170014457Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.Type: ApplicationFiled: September 8, 2016Publication date: January 19, 2017Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves MILLET, Sarah ROWE
-
Publication number: 20170014458Abstract: The disclosure relates to a mucoadhesive sustained-release vaginal tablet including at least one probiotic strain of the genus Lactobacillus compressed with an excipient suitable for conferring upon the tablet the properties of vaginal wall mucoadhesion and sustained release.Type: ApplicationFiled: March 10, 2015Publication date: January 19, 2017Applicant: BIOSEInventors: Claudia THORAL, Pierre TCHORELOFF, Vincent MAZEL, Virginie BUSIGNIES, Adrien NIVOLIEZ
-
Publication number: 20170014459Abstract: The present invention provides a topical composition comprising extract from Coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent, in particular, human papiloma virus infections and related disorders, including cervical cancer. The composition of the invention acts enhancing genital immunity against infectious agents and re-epithelising damaged tissue.Type: ApplicationFiled: March 13, 2015Publication date: January 19, 2017Inventors: Fernando LOSA DOMINGUEZ, Santiago PALACIOS, Yann GASLAIN
-
Publication number: 20170014460Abstract: An extract of Carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed is used as an inhibitor of HIF to effectively block hypoxia-inducible factor (HIF) function and methods of use thereof. More specifically it relates to the use of the Carica papaya plant extract to eliminate unwanted cells by inhibiting HIF in the prevention and treatment of hypoxia-related conditions and diseases such as inflammatory diseases, vascular diseases, cancer and infectious diseases. In a particular embodiment, a solid hypoxic tumor in a patient is treated by administering to the patient a therapeutically acceptable amount of an extract of Carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed, preferably an alcohol extract such as a methanol extract, whereby to inhibit hypoxia-inducible factors in the tumor.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Applicants: The Regents of the University of California, Universiti Putra MalaysiaInventors: Eric J. Stanbridge, Norazizah Shafee, Khatijah Yusoff
-
Publication number: 20170014461Abstract: Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Artemisia extract, at least one Aloe gel powder, and at least one Schizandra extract. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Artemisia extract enriched for at least one polymer or biopolymer, at least one Aloe gel powder enriched for at least one chromone, and at least one Schizandra extract enriched for at least one lignan and organic acid.Type: ApplicationFiled: July 12, 2016Publication date: January 19, 2017Applicant: Unigen, Inc.Inventors: Qi Jia, Mesfin Yimam, Ping Jiao, Mei Feng Hong, Breanna Moore
-
Publication number: 20170014462Abstract: The invention relates to a bone and joint protection composition and use thereof. According to the composition, the four Chinese medicinal herbs Eucommiae Cortex, Achyranthis Bidentatae Radix, Astragali Radix and Chuanxiong Rhizoma are used, and the effects of enhancing the bone density, preventing and relieving osteoporosis, restraining the activity of osteoclast, promoting the function of bone cells, increasing the formation of calcified bone, promoting cartilage repair, delaying joint recession and repairing joint damage are achieved through multiple approaches and multiple levels. On the basis, by adding glucosamine hydrochloride, chondroitin sulfate and/or collagen, the bone density can be enhanced, the osteoporosis can be prevented and treated; the activity of the osteoclast can be restrained, the function of bone cells can be promoted, the formation of calcified bone can be increased, the cartilage repair can be promoted, joint recession can be delayed, and the joint damage can be repaired.Type: ApplicationFiled: July 13, 2016Publication date: January 19, 2017Applicant: INFINITUS (CHINA) COMPANY LTD.Inventors: Bin SHI, Xiaolei GUO, Chung Wah MA, Wei ZHANG, Zhen LUO
-
Publication number: 20170014463Abstract: A composition including plant extracts that synergistically treat or inhibit pathological conditions and a method for developing the composition is provided. The composition includes bioactive chemical agents extracted from the Plantago major plant species including, but not limited to, acetonide, catalpol, hispidulin, loliolide, neptin, rhamnose, and scutellarin, and bioactive chemical agents extracted from the Mentha spicata plant species including, but not limited to, cadinol, diosmetin, eugenol, furfural, hesperidin, luteolin, and piperitone. The method includes the steps of washing Plantago major and Mentha spicata plant material, freezing the plant material, cutting the frozen plant material into pieces, heating the plant material in purified water to form a resultant solution containing Plantago major and Mentha spicata plant extracts, cooling the resultant solution, and filtering the Plantago major and Mentha spicata plant material out of the resultant solution to produce the composition.Type: ApplicationFiled: July 14, 2016Publication date: January 19, 2017Inventor: Bruce Nolan
-
Publication number: 20170014464Abstract: The present invention discloses an herbal composition comprising a therapeutic effective amount of Cascalote (Caesalpinia coriaria) and a therapeutic effective amount of Ruda (Ruta graveolens). In another implementation, the herbal composition can also comprise of an effective amount of at least one pharmaceutically acceptable excipient for application to the body, including skin and tissue. The disclosed invention also includes a method for making the herbal composition and a method of application of the herbal composition.Type: ApplicationFiled: July 18, 2016Publication date: January 19, 2017Inventor: Fernando Blanco Rodriguez
-
Publication number: 20170014465Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Andreas T. GRASSAUER, Eva PRIESCHL
-
Publication number: 20170014466Abstract: A process for producing a distilled ethanol product comprising an antioxidant component and an ethanol component is described. In the process, plant matter containing antioxidants is washed, frozen and exposed to an input volume of ethanol. Antioxidants are ethanolically extracted from the frozen plant matter. The plant matter and the liquid ethanol fractions are then separated and the plant matter having antioxidants extracted therefrom is used to produce ethanol which is subsequently used to extract antioxidants from a second batch of plant matter. The ethanol fraction having antioxidants therein is stored or diluted for later use.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Inventors: Alan B. Gillis, Judith M. Gillis
-
Publication number: 20170014467Abstract: The present invention relates to the pharmaceutical field, particularly to a composition and the use thereof. The composition serves to lower uric acid through the combination of several traditional Chinese medicines of Smilacis Glabra Rhizoma, Cichorii Herba, Plantaginis Herba and Coicis semen. On the basis of the combination of the traditional Chinese medicines described above, the addition of Alismatis Rhizoma is able to improve the effect of lowering uric acid more significantly. Further, on the basis of the combination of the traditional Chinese medicines described above, the addition of tuna was able to improve the effect of lowering uric acid more significantly. A comprehensive analysis of the experimental results described above indicates that the compositions provided in the present invention have a significant effect of lowering uric acid.Type: ApplicationFiled: June 7, 2016Publication date: January 19, 2017Applicant: INFINITUS (CHINA) COMPANY LTD.Inventors: Bin SHI, Xiaolei GUO, Chung Wah MA, Chuixin QIN, Zhen LUO, Wei ZHANG